Literature DB >> 8613000

Long-term survival in patients with hereditary hemochromatosis.

C Niederau1, R Fischer, A Pürschel, W Stremmel, D Häussinger, G Strohmeyer.   

Abstract

BACKGROUND & AIMS: The course of hereditary hemochromatosis may depend on the degree of iron overload and the time of therapeutic intervention. This analysis evaluates the impact of early diagnosis and iron removal on survival and complications in hereditary hemochromatosis.
METHODS: A Cohort of 251 patients with hemochromatosis was followed up for 14.1 +/- 6.8 years.
RESULTS: Survival was reduced in the total group of patients when compared with a matched normal population. Survival in noncirrhotic and nondiabetic patients and in patients diagnosed between 1982 and 1991 was identical with rates expected. Survival was reduced in patients with severe iron overload vs. those with less severe overload. The percentage of early diagnoses increased threefold between 1947 and 1969 to that between 1970 and 1981; there was only a further 20%-25% increase in the last decade. Deaths caused by liver cancer, cardiomyopathy, liver cirrhosis, and diabetes mellitus were increased as compared with expected rates. Liver cancers were associated with cirrhosis and amount of mobilizable iron but not with hepatitis B or C markers.
CONCLUSIONS: Prognosis of hemochromatosis and most of its complications, including liver cancer, depend on the amount and duration of iron excess. Early diagnosis and therapy largely prevent the adverse consequences of iron overload.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613000     DOI: 10.1053/gast.1996.v110.pm8613000

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  140 in total

1.  Hereditary haemochromatosis: to screen or not. Conditions for screening are not yet fulfilled.

Authors:  J E Haddow; L A Bradley
Journal:  BMJ       Date:  1999-08-28

Review 2.  Controversy in primary care: Should asymptomatic haemochromatosis be treated?

Authors:  C J Seamark; M Hutchinson
Journal:  BMJ       Date:  2000-05-13

3.  Diabetes and HFE mutations: cause or coincidence?

Authors:  Linda E Pinsky; Giuseppina Imperatore; Wylie Burke
Journal:  West J Med       Date:  2002-03

4.  Hereditary haemochromatosis: never seen a case?

Authors:  J Emery; P Rose
Journal:  Br J Gen Pract       Date:  2001-05       Impact factor: 5.386

5.  The case for strengthening education and training for general practice.

Authors:  T van Zwanenberg; M Pringle; S Smail; M Baker; S Field
Journal:  Br J Gen Pract       Date:  2001-05       Impact factor: 5.386

6.  Variable phenotypic presentation of iron overload in H63D homozygotes: are genetic modifiers the cause?

Authors:  P Aguilar-Martinez; M Bismuth; M C Picot; C Thelcide; G P Pageaux; F Blanc; P Blanc; J F Schved; D Larrey
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

7.  Global prevalence of putative haemochromatosis mutations.

Authors:  A T Merryweather-Clarke; J J Pointon; J D Shearman; K J Robson
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

8.  Bone status in a mouse model of genetic hemochromatosis.

Authors:  P Guggenbuhl; P Fergelot; M Doyard; H Libouban; M-P Roth; Y Gallois; G Chalès; O Loréal; D Chappard
Journal:  Osteoporos Int       Date:  2010-10-26       Impact factor: 4.507

Review 9.  Hepatocellular carcinoma: updates in primary prevention.

Authors:  Will J Fecht; Alex S Befeler
Journal:  Curr Gastroenterol Rep       Date:  2004-02

10.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.